6931.Tw
The company operates in the healthcare facilities and services industry, specializing in biotechnology, and generates revenue primarily through the provision of healthcare services and equipment.
Business. The company operates in the healthcare facilities and services industry, specializing in biotechnology, and generates revenue primarily through the provision of healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare facilities and services industry, specializing in biotechnology, and generates revenue primarily through the provision of healthcare services and equipment.
The company's capital structure is characterized by a debt-to-equity ratio of 1.05, indicating a moderate level of leverage. Its liquidity position is marked by a current ratio of 3.93, suggesting the company has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -71.63 million TWD, which may raise concerns about its ability to fund operations without external financing.
In terms of profitability, the company's return on equity is 8.02%, and its return on assets is 3.55%. These figures are to be compared against the industry's preferred metrics and cohort medians to assess performance. The company's net income of 91.704 million TWD indicates a profitable operation, but the gross profit margin of 13.16% (147.623 million TWD / 1.121696 billion TWD) suggests there is room for improvement in cost management.
The company's revenue is not segmented by geographic regions or business lines in the provided data, so it is not possible to determine the geographic exposure or revenue concentration. The lack of segment data limits the ability to assess the diversification of the company's revenue streams.
The company's growth trajectory is not explicitly detailed in the provided data. The outlook for the current and next fiscal years is not specified, and there are no numeric deltas provided to indicate the expected growth or decline in revenue. The company's capital expenditure of -80.489 million TWD suggests a reduction in investment in long-term assets, which could impact future growth.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue. The dilution risk is low, suggesting that the company is not expected to issue additional shares that could dilute existing shareholders' equity in the near term.
There are no recent events, such as filings or transcripts, provided in the data to inform the company's current situation or strategic direction. The absence of such information limits the ability to assess the company's response to market changes or internal developments.
- The company has a moderate level of leverage with a debt-to-equity ratio of 1.05.
- The company's liquidity position is strong with a current ratio of 3.93.
- The company is profitable with a net income of 91.704 million TWD, but its gross profit margin is relatively low.
- The company's capital expenditure is negative, indicating a reduction in investment in long-term assets.
- The company has a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6931.TW Market data — financials · 2026-05-27